Emerging functions of serum amyloid A in inflammation

Journal of Leukocyte Biology

Volumn 98, Issue 6, 2015, Pages 923-929

  Ye, Richard D ^a   Sun, Lei ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF MACAU   (Macao)

Author keywords

Acute phase reactants; Cytokines; Epigenetic regulation; Stress response

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; JMJD3 PROTEIN; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; PURINERGIC P2X7 RECEPTOR; RECOMBINANT PROTEIN; SCAVENGER RECEPTOR BI; SERUM AMYLOID A; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; HISTONE DEMETHYLASE; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; KDM6B PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN; P2XR RECEPTOR, HUMAN; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

EPIGENETICS; HOMEOSTASIS; INFLAMMATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; ACUTE PHASE RESPONSE; ANIMAL; HUMAN; IMMUNOLOGY; PATHOLOGY;

ACUTE-PHASE REACTION; ADENOSINE TRIPHOSPHATE; ANIMALS; HUMANS; INTERFERON REGULATORY FACTORS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LIPOPOLYSACCHARIDES; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; RECEPTORS, PURINERGIC P2X7; SCAVENGER RECEPTORS, CLASS B; SERUM AMYLOID A PROTEIN; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84948952956     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.3VMR0315-080R     Document Type: Review

References (76)

1. Kushner, I., Rzewnicki, D. (1999) Acute phase response. In Inflammation: Basic Principles and Clinical Correlates (J. I. Gallin, R. Snyderman, eds.), Lippincott Willams & Wilkins, Philadelphia, 317–329.
2. Gabay, C., Kushner, I. (1999) Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340, 448–454.
3. Meek, R. L., Eriksen, N., Benditt, E. P. (1992) Murine serum amyloid A3 is a high density apolipoprotein and is secreted by macrophages. Proc. Natl. Acad. Sci. USA 89, 7949–7952.
4. O’Hara, R., Murphy, E. P., Whitehead, A. S., FitzGerald, O., Bresnihan, B. (2000) Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res. 2, 142–144.
5. Vallon, R., Freuler, F., Desta-Tsedu, N., Robeva, A., Dawson, J., Wenner, P., Engelhardt, P., Boes, L., Schnyder, J., Tschopp, C., Urfer, R., Baumann, G. (2001) Serum amyloid A (apoSAA) expression is upregulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J. Immunol. 166, 2801–2807.
6. Meek, R. L., Urieli-Shoval, S., Benditt, E. P. (1994) Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc. Natl. Acad. Sci. USA 91, 3186–3190.
7. Wilson, P. G., Thompson, J. C., Webb, N. R., de Beer, F. C., King, V. L., Tannock, L. R. (2008) Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am. J. Pathol. 173, 1902–1910.
8. Dong, Z., Wu, T., Qin, W., An, C., Wang, Z., Zhang, M., Zhang, Y., Zhang, C., An, F. (2011) Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Mol. Med. 17, 1357–1364.
9. Niederau, C., Backmerhoff, F., Schumacher, B., Niederau, C. (1997) Inflammatory mediators and acute phase proteins in patients with Crohn’s disease and ulcerative colitis. Hepatogastroenterology 44, 90–107.
10. Marzi, C., Albrecht, E., Hysi, P. G., Lagou, V., Waldenberger, M., Tönjes, A., Prokopenko, I., Heim, K., Blackburn, H., Ried, J. S., Kleber, M. E., Mangino, M., Thorand, B., Peters, A., Hammond, C. J., Grallert, H., Boehm, B. O., Kovacs, P., Geistlinger, L., Prokisch, H., Winkelmann, B. R., Spector, T. D., Wichmann, H. E., Stumvoll, M., Soranzo, N., März, W., Koenig, W., Illig, T., Gieger, C. (2010) Genomewide association study identifies two novel regions at 11p15.5-p13 and 1p31 with major impact on acute-phase serum amyloid A. PLoS Genet. 6, e1001213.
11. Marzi, C., Huth, C., Herder, C., Baumert, J., Thorand, B., Rathmann, W., Meisinger, C., Wichmann, H. E., Roden, M., Peters, A., Grallert, H., Koenig, W., Illig, T. (2013) Acute-phase serum amyloid A protein and its implication in the development of type 2 diabetes in the KORA S4/F4 study. Diabetes Care 36, 1321–1326.
12. Uhlar, C. M., Whitehead, A. S. (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265, 501–523.
13. Sellar, G. C., Whitehead, A. S. (1993) Localization of four human serum amyloid A (SAA) protein superfamily genes to chromosome 11p: characterization of a fifth SAA-related gene sequence. Genomics 16, 774–776.
14. Jensen, L. E., Whitehead, A. S. (1998) Regulation of serum amyloid A protein expression during the acute-phase response. Biochem. J. 334, 489–503.
15. Uhlar, C. M., Burgess, C. J., Sharp, P. M., Whitehead, A. S. (1994) Evolution of the serum amyloid A (SAA) protein superfamily. Genomics 19, 228–235.
16. Lowell, C. A., Potter, D. A., Stearman, R. S., Morrow, J. F. (1986) Structure of the murine serum amyloid A gene family. Gene conversion. J. Biol. Chem. 261, 8442–8452.
17. Meek, R. L., Benditt, E. P. (1986) Amyloid A gene family expression in different mouse tissues. J. Exp. Med. 164, 2006–2017.
18. Butler, A., Whitehead, A. S. (1996) Mapping of the mouse serum amyloid A gene cluster by long-range polymerase chain reaction. Immunogenetics 44, 468–474.
19. Chiba, T., Han, C. Y., Vaisar, T., Shimokado, K., Kargi, A., Chen, M. H., Wang, S., McDonald, T. O., O’Brien, K. D., Heinecke, J. W., Chait, A. (2009) Serum amyloid A3 does not contribute to circulating SAA levels. J. Lipid Res. 50, 1353–1362.
20. Benditt, E. P., Eriksen, N. (1977) Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc. Natl. Acad. Sci. USA 74, 4025–4028.
21. Banka, C. L., Yuan, T., de Beer, M. C., Kindy, M., Curtiss, L. K., de Beer, F. C. (1995) Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J. Lipid Res. 36, 1058–1065.
22. Shah, C., Hari-Dass, R., Raynes, J. G. (2006) Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood 108, 1751–1757.
23. Derebe, M. G., Zlatkov, C. M., Gattu, S., Ruhn, K. A., Vaishnava, S., Diehl, G. E., MacMillan, J. B., Williams, N. S., Hooper, L. V. (2014) Serum amyloid A is a retinol binding protein that transports retinol during bacterial infection. Elife 3, e03206.
24. Badolato, R., Wang, J. M., Murphy, W. J., Lloyd, A. R., Michiel, D. F., Bausserman, L. L., Kelvin, D. J., Oppenheim, J. J. (1994) Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J. Exp. Med. 180, 203–209.
25. Su, S. B., Gong, W., Gao, J. L., Shen, W., Murphy, P. M., Oppenheim, J. J., Wang, J. M. (1999) A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med. 189, 395–402.
26. Patel, H., Fellowes, R., Coade, S., Woo, P. (1998) Human serum amyloid A has cytokine-like properties. Scand. J. Immunol. 48, 410–418.
27. Furlaneto, C. J., Campa, A. (2000) A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem. Biophys. Res. Commun. 268, 405–408.
28. He, R., Sang, H., Ye, R. D. (2003) Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 101, 1572–1581.
29. O’Hara, R., Murphy, E. P., Whitehead, A. S., FitzGerald, O., Bresnihan, B. (2004) Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum. 50, 1788–1799.
30. Cai, H., Song, C., Endoh, I., Goyette, J., Jessup, W., Freedman, S. B., McNeil, H. P., Geczy, C. L. (2007) Serum amyloid A induces monocyte tissue factor. J. Immunol. 178, 1852–1860.
31. He, R., Shepard, L. W., Chen, J., Pan, Z. K., Ye, R. D. (2006) Serum amyloid A is an endogenous ligand that differentially induces IL-12 and IL-23. J. Immunol. 177, 4072–4079.
32. He, R. L., Zhou, J., Hanson, C. Z., Chen, J., Cheng, N., Ye, R. D. (2009) Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 113, 429–437.
33. Lu, J., Yu, Y., Zhu, I., Cheng, Y., Sun, P. D. (2014) Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. Proc. Natl. Acad. Sci. USA 111, 5189–5194.
34. Cheng, N., He, R., Tian, J., Ye, P. P., Ye, R. D. (2008) Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J. Immunol. 181, 22–26.
35. De Santo, C., Arscott, R., Booth, S., Karydis, I., Jones, M., Asher, R., Salio, M., Middleton, M., Cerundolo, V. (2010) Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat. Immunol. 11, 1039–1046.
36. Sun, L., Zhu, Z., Cheng, N., Yan, Q., Ye, R. D. (2014) Serum amyloid A induces interleukin-33 expression through an IRF7-dependent pathway. Eur. J. Immunol. 44, 2153–2164.
37. Sun, L., Zhou, H., Zhu, Z., Yan, Q., Wang, L., Liang, Q., Ye, R. D. (2015) Ex vivo and in vitro effect of serum amyloid a in the induction of macrophage m2 markers and efferocytosis of apoptotic neutrophils. J. Immunol. 194, 4891–4900.
38. Migeotte, I., Communi, D., Parmentier, M. (2006) Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 17, 501–519.
39. Ye, R. D., Boulay, F., Wang, J. M., Dahlgren, C., Gerard, C., Parmentier, M., Serhan, C. N., Murphy, P. M. (2009) International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61, 119–161.
40. Sodin-Semrl, S., Spagnolo, A., Mikus, R., Barbaro, B., Varga, J., Fiore, S. (2004) Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int. J. Immunopathol. Pharmacol. 17, 145–156.
41. Ren, S. W., Qi, X., Jia, C. K., Wang, Y. Q. (2014) Serum amyloid A and pairing formyl peptide receptor 2 are expressed in corneas and involved in inflammation-mediated neovascularization. Int. J. Ophthalmol. 7, 187–193.
42. El Kebir, D., József, L., Khreiss, T., Pan, W., Petasis, N. A., Serhan, C. N., Filep, J. G. (2007) Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J. Immunol. 179, 616–622.
43. Sandri, S., Rodriguez, D., Gomes, E., Monteiro, H. P., Russo, M., Campa, A. (2008) Is serum amyloid A an endogenous TLR4 agonist? J. Leukoc. Biol. 83, 1174–1180.
44. Lee, J. M., Kim, E. K., Seo, H., Jeon, I., Chae, M. J., Park, Y. J., Song, B., Kim, Y. S., Kim, Y. J., Ko, H. J., Kang, C. Y. (2014) Serum amyloid A3 exacerbates cancer by enhancing the suppressive capacity of myeloidderived suppressor cells via TLR2-dependent STAT3 activation. Eur. J. Immunol. 44, 1672–1684.
45. Baranova, I. N., Vishnyakova, T. G., Bocharov, A. V., Kurlander, R., Chen, Z., Kimelman, M. L., Remaley, A. T., Csako, G., Thomas, F., Eggerman, T. L., Patterson, A. P. (2005) Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J. Biol. Chem. 280, 8031–8040.
46. Cai, L., de Beer, M. C., de Beer, F. C., van der Westhuyzen, D. R. (2005) Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J. Biol. Chem. 280, 2954–2961.
47. Kluve-Beckerman, B., Manaloor, J. J., Liepnieks, J. J. (2002) A pulsechase study tracking the conversion of macrophage-endocytosed serum amyloid A into extracellular amyloid. Arthritis Rheum. 46, 1905–1913.
48. Ather, J. L., Ckless, K., Martin, R., Foley, K. L., Suratt, B. T., Boyson, J. E., Fitzgerald, K. A., Flavell, R. A., Eisenbarth, S. C., Poynter, M. E. (2011) Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J. Immunol. 187, 64–73.
49. Niemi, K., Teirilä, L., Lappalainen, J., Rajamäki, K., Baumann, M. H., Öörni, K., Wolff, H., Kovanen, P. T., Matikainen, S., Eklund, K. K. (2011) Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J. Immunol. 186, 6119–6128.
50. Christenson, K., Björkman, L., Tängemo, C., Bylund, J. (2008) Serum amyloid A inhibits apoptosis of human neutrophils via a P2X7-sensitive pathway independent of formyl peptide receptor-like 1. J. Leukoc. Biol. 83, 139–148.
51. Satoh, T., Takeuchi, O., Vandenbon, A., Yasuda, K., Tanaka, Y., Kumagai, Y., Miyake, T., Matsushita, K., Okazaki, T., Saitoh, T., Honma, K., Matsuyama, T., Yui, K., Tsujimura, T., Standley, D. M., Nakanishi, K., Nakai, K., Akira, S. (2010) The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat. Immunol. 11, 936–944.
52. Yan, Q., Sun, L., Zhu, Z., Wang, L., Li, S., Ye, R. D. (2014) Jmjd3- mediated epigenetic regulation of inflammatory cytokine gene expression in serum amyloid A-stimulated macrophages. Cell. Signal. 26, 1783–1791.
53. Matzinger, P. (2007) Friendly and dangerous signals: is the tissue in control? Nat. Immunol. 8, 11–13.
54. Seong, S. Y., Matzinger, P. (2004) Hydrophobicity: an ancient damageassociated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4, 469–478.
55. Mullick, A. E., Tobias, P. S., Curtiss, L. K. (2005) Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest. 115, 3149–3156.
56. Tobias, P. S., Curtiss, L. K. (2008) TLR2 in murine atherosclerosis. Semin. Immunopathol. 30, 23–27.
57. Van den Brand, B., Waterborg, C., van den Berg, W., van de Loo, F. (2013) Is the serum amyloid A we use really serum amyloid A? Comment on the article by Connolly et al. Arthritis Rheum. 65, 283–284.
58. Björkman, L., Raynes, J. G., Shah, C., Karlsson, A., Dahlgren, C., Bylund, J. (2010) The proinflammatory activity of recombinant serum amyloid A is not shared by the endogenous protein in the circulation. Arthritis Rheum. 62, 1660–1665.
59. Kim, M. H., de Beer, M. C., Wroblewski, J. M., Webb, N. R., de Beer, F. C. (2013) SAA does not induce cytokine production in physiological conditions. Cytokine 61, 506–512.
60. Chen, M., Zhou, H., Cheng, N., Qian, F., Ye, R. D. (2014) Serum amyloid A1 isoforms display different efficacy at Toll-like receptor 2 and formyl peptide receptor 2. Immunobiology 219, 916–923.
61. Hiratsuka, S., Watanabe, A., Sakurai, Y., Akashi-Takamura, S., Ishibashi, S., Miyake, K., Shibuya, M., Akira, S., Aburatani, H., Maru, Y. (2008) The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a premetastatic phase. Nat. Cell Biol. 10, 1349–1355.
62. Deguchi, A., Tomita, T., Omori, T., Komatsu, A., Ohto, U., Takahashi, S., Tanimura, N., Akashi-Takamura, S., Miyake, K., Maru, Y. (2013) Serum amyloid A3 binds MD-2 to activate p38 and NF-kB pathways in a MyD88- dependent manner. J. Immunol. 191, 1856–1864.
63. Shigemura, H., Ishiguro, N., Inoshima, Y. (2014) Up-regulation of MUC2 mucin expression by serum amyloid A3 protein in mouse colonic epithelial cells. J. Vet. Med. Sci. 76, 985–991.
64. Tsan, M. F., Gao, B. (2004) Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 76, 514–519.
65. Webb, N. R., de Beer, M. C., van der Westhuyzen, D. R., Kindy, M. S., Banka, C. L., Tsukamoto, K., Rader, D. L., de Beer, F. C. (1997) Adenoviral vector-mediated overexpression of serum amyloid A in apoAI- deficient mice. J. Lipid Res. 38, 1583–1590.
66. Kindy, M. S., King, A. R., Yu, J., Gerardot, C., Whitley, J., de Beer, F. C. (1998) Adenoviral expression of murine serum amyloid A proteins to study amyloid fibrillogenesis. Biochem. J. 332, 721–728.
67. Kindy, M. S., de Beer, M. C., Yu, J., de Beer, F. C. (2000) Expression of mouse acute-phase (SAA1.1) and constitutive (SAA4) serum amyloid A isotypes: influence on lipoprotein profiles. Arterioscler. Thromb. Vasc. Biol. 20, 1543–1550.
68. Olsson, M., Ahlin, S., Olsson, B., Svensson, P. A., Ståhlman, M., Borén, J., Carlsson, L. M., Sjöholm, K. (2011) Establishment of a transgenic mouse model specifically expressing human serum amyloid A in adipose tissue. PLoS ONE 6, e19609.
69. Den Hartigh, L. J., Wang, S., Goodspeed, L., Ding, Y., Averill, M., Subramanian, S., Wietecha, T., O’Brien, K. D., Chait, A. (2014) Deletion of serum amyloid A3 improves high fat high sucrose diet-induced adipose tissue inflammation and hyperlipidemia in female mice. PLoS ONE 9, e108564.
70. O’Reilly, S., Cant, R., Ciechomska, M., Finnigan, J., Oakley, F., Hambleton, S., van Laar, J. M. (2014) Serum amyloid A induces interleukin-6 in dermal fibroblasts via Toll-like receptor 2, interleukin-1 receptor-associated kinase 4 and nuclear factor-kB. Immunology 143, 331–340.
71. Hansen, M. T., Forst, B., Cremers, N., Quagliata, L., Ambartsumian, N., Grum-Schwensen, B., Klingelhöfer, J., Abdul-Al, A., Herrmann, P., Osterland, M., Stein, U., Nielsen, G. H., Scherer, P. E., Lukanidin, E., Sleeman, J. P., Grigorian, M. (2015) A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene 34, 424–435.
72. Gouwy, M., De Buck, M., Pörtner, N., Opdenakker, G., Proost, P., Struyf, S., Van Damme, J. (2015) Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines. Eur. J. Immunol. 45, 101–112.
73. Anthony, D., McQualter, J. L., Bishara, M., Lim, E. X., Yatmaz, S., Seow, H. J., Hansen, M., Thompson, M., Hamilton, J. A., Irving, L. B., Levy, B. D., Vlahos, R., Anderson, G. P., Bozinovski, S. (2014) SAA drives proinflammatory heterotypic macrophage differentiation in the lung via CSF-1R-dependent signaling. FASEB J. 28, 3867–3877.
74. De Beer, M. C., Wroblewski, J. M., Noffsinger, V. P., Rateri, D. L., Howatt, D. A., Balakrishnan, A., Ji, A., Shridas, P., Thompson, J. C., van der Westhuyzen, D. R., Tannock, L. R., Daugherty, A., Webb, N. R., De Beer, F. C. (2014) Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 34, 255–261.
75. Thompson, J. C., Jayne, C., Thompson, J., Wilson, P. G., Yoder, M. H., Webb, N., Tannock, L. R. (2015) A brief elevation of serum amyloid A is sufficient to increase atherosclerosis. J. Lipid Res. 56, 286–293.
76. Webb, N. R., De Beer, M. C., Wroblewski, J. M., Ji, A., Bailey, W., Shridas, P., Charnigo, R. J., Noffsinger, V. P., Witta, J., Howatt, D. A., Balakrishnan, A., Rateri, D. L., Daugherty, A., De Beer, F. C. (2015) Deficiency of endogenous acute-phase serum amyloid A protects apoE2/2 mice from angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler. Thromb. Vasc. Biol. 35, 1156–1165.